You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信邦製藥(002390.SZ)擬終止部分募投項目並永久補充流動資金
格隆匯 01-20 15:14

格隆匯1月20日丨信邦製藥(002390.SZ)公佈,公司於2020年1月17日召開第七屆董事會第十八次會議和第七屆監事會第十六次會議,審議通過了《關於終止部分募集資金投資項目並永久補充流動資金的議案》。董事會同意公司終止實施募集資金投資項目“多肽產能擴建技術改造項目”、“診斷試劑及多肽製劑產業基地技術改造項目”,並將回收資金永久補充公司流動資金。

該議案尚需提請公司股東大會進行審議,待股東大會審議通過後實施。

康永生物體外診斷試劑產品的客户主要集中在美國,受到市場競爭加劇而新市場拓展未達預期等因素的影響,導致體外診斷試劑產品的單價和銷售量都出現了較大幅度的下滑,原募投項目的投資回報存在較大不確定性。多肽產品方面,隨着FDA批准了多款口服多肽藥物,原料藥的需求大幅提升,巨大的新增產能變化也會增加很多環保的壓力與成本,原募投項目需要做較大調整,資金投入、實施方式、預期回報等存在不確定性。因此,為了降低募集資金的投資風險,充分發揮募集資金的使用效益,公司決定終止實施上述募投項目,並將上述項目原規劃投資的6.3億元募集資金全部收回,其中已使用的部分募集資金由中肽生化、康永生物以自有資金補足,項目後續實施視市場情況進行。

為最大限度發揮募集資金的使用效益,降低公司財務費用,為公司和公司股東創造更大的效益,公司擬將上述擬終止的募投項目原規劃投資的6.3全部收回,其中已使用的部分募集資金由中肽生化(含中肽生化分立後新設公司康永生物)以自有資金補足回收的資金全部用於永久補充公司流動資金。公司將於上述項目回收資金永久補充流動資金後註銷項目募集資金專項賬户,專項賬户註銷後,公司、中肽生化獨立財務顧問、開户銀行簽署的募集資金監管協議隨之終止。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account